Navigation Links
Zenobia Therapeutics Announce A Partnership With The Alzheimer's Drug Discovery Foundation
Date:8/14/2012

LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Zenobia Therapeutics, the leader in fragment-based lead discovery for CNS disease announce today a strategic partnership to provide ADDF researchers access to Zenobia's unique discovery platform. 

The Zenobia team is composed of leaders in the fields of high-throughput structural biology and fragment-based lead discovery (FBLD).  Their founders are pioneers of crystallographic and NMR fragment screening, and Zenobia's FBLD approach is proven to identify specific and brain penetrable small molecules for central nervous system (CNS) indications.  The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila).  Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.

For ADDF researchers, Zenobia will provide complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses.  In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating neurodegenerative diseases which there is no disease altering treatment such as Alzheimer's, Parkinson's and Huntington's disease.  For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit www.zenobiatherapeutics.com. For additional information on Zenobia's Fragment Library 1 or 2, contact Erika Zehm at erika@zenobiatherapeutics.com.

About the Alzheimer's Drug Discovery Foundation

The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $51 million to fund over 370 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information about the ADDF, please visit www.alzdiscovery.org.


'/>"/>
SOURCE Zenobia Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a ... survey in an infographic on the current state of anxiety in support of National ... anxiety, was conducted in April 2017 and benchmarked general anxiety levels as well as ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... PITTSBURGH, PA (PRWEB) , ... May 22, 2017 , ... ... way to write with a pen. "My wife’s hand was damaged in a firework ... invent something that helps people with manual problems." , He then designed and created ...
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
(Date:5/21/2017)... ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, ... most respected lead singers in the rock industry would take his own life, but the ... investigates how mental illness played a role in the death of Chris Cornell . ...
Breaking Medicine News(10 mins):